Selinexor in MPNs: Optimizing What's Available

Kapila Viges, of the MPN Research Foundation, and John Mascarenhas, MD, of the Icahn School of Medicine, discuss the evolving role of selinexor in MPN treatment. Currently, selinexor presents an opportunity to deepen response early in treatment, but key questions remain. Should it be used upfront for a stronger initial response, or would it offer greater benefit as a second-line therapy? The potential of selinexor as a maintenance treatment is also being explored. Viges and Dr. Mascarenhas emphasize the need for ongoing commitment from physicians, sponsors, and the patient community to ensure long-term follow-up and answer these critical research questions.